Abstract:Background: Bispecific antibodies (BsAb) and Chimeric antigen receptor T-cell therapy (CAR-T) have emerged as a promising treatment option for patients with relapsed, refractory multiple myeloma (RRMM) for greater than four previous lines of therapy. The efficacy of these novel drugs in extramedullary disease (EMD) and high-risk cytogenetic abnormalities (HRCA) is relatively less reported. The purpose of this systematic review and meta-analysis is to compare the efficacy of BsAbs vs CAR-T in the treatment of EMD and HRCAs in RRMM. Methods: A systematic literature search was conducted to identify clinical trials that investigated BsAbs and CAR-T therapies in treating RRMM patients using the PubMed, Cochrane, ASH 2022 and ASCO 2023 abstracts using search terms (bispecific antibodies) AND (multiple myeloma), (CAR T cell therapy) AND (multiple myeloma). For BsAbs, our search on PubMed yielded 263 studies. 7 were clinical trials and 5 of these were included. 6 ASH abstracts and one ASCO abstract were also included resulting in a total of 12 studies considered for this meta-analysis. For CAR-T, our search on PubMed and COCHRANE yielded 84 and 20 studies respectively. After screening, we have included 21 studies and 6 ASCO abstracts in final analysis. RStudio Desktop Version 2023.03.0+ 386 was used for statistical analysis. Cochrane-Q test and I2 statistic were used to assess the statistical heterogenicity. Fixed effect model was used for low statistical heterogeneity (P > 0.05 in Cochrane-Q test and I2 < 50%), while a random effect model was used for high statistical heterogeneity (P < 0.05 in Cochrane-Q test and I2 > 50%). Categorical outcomes were summarized by pooled proportion with 95% CI. Subgroup analysis was performed wherever required. P <0.05 was considered statistically significant. Results Bispecific antibodies Overall response rates (ORR) were reported in a study population of 823 patients across 12 studies. The ORR was reported in 4 studies (n=106) for EMD and 4 studies (n=100) for HRCA respectively. The pooled ORR was 0.67 [95% CI; 0.59; 0.76) for the whole group. The pooled ORR was 0.48 (95% CI of 0.31 to 0.65) for EMD and 0.60 (95% CI of 0.51 to 0.70) for HRCA respectively. Subgroup analysis showed that there was a statistically significant difference in overall response rate according to different targets. However, there was no statistically significant difference in the ORR between the drugs with respect to EMD and HRCA. Combination therapy of Teclistamab and Talquetamab has highest ORR and RR in EMD disease compared to other BsABs in a study by Cohen et al. Funnel plot is symmetrical and showed no probability of publication bias for overall response rate for bispecific antibodies with a p-value of 0.676. CAR T cell therapy ORR with CAR-T cell therapy was reported across 27 studies with pooled sample size of 1469. The ORR was reported in 14 studies (n=172) for EMD and 11 studies (n=268) for HRCAs, respectively. The pooled ORR was 0.86 (95% CI of 0.82 to 0.90). The pooled proportion of RR among MM patients with EMD and HRCAs was 0.77 (95% CI of 0.68 to 0.87) and 0.77 (95% CI of 0.69 to 0.86), respectively. Funnel plot asymmetry showed possible publication bias for overall response rate for CAR T cell therapy with p-value of 0.021. Bispecific antibodies vs CAR-T. ORR in the whole cohort (P <0.001), EMD cohort (P <0.001), and HRCA cohort (P <0.046) were found to be significantly higher in CAR-T cell therapy as compared to bispecific antibodies. Conclusion: BsABs and CAR-T cell therapy are effective treatment options for relapsed MM patients.ORR in the whole cohort, EMD cohort, and HRCA cohort were found to be superior with CAR T cell therapy. However, it is difficult to make direct comparisons of pooled estimates of two different therapies. There was no significant difference in EMD and HRCA between the different types of BsAb therapy. Better reporting of EMD responses is urgently needed in published clinical data to know the true effect size and develop strategies to overcome this.

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas

Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma

Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

A research center's experience of T-cell redirecting therapies in triple-class refractory multiple myeloma

Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma

Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy

CAR T‐cell therapy in large B cell lymphoma

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

Efficacy of Bispecific Antibodies Vs CAR-T in the Treatment of Extramedullary Disease and High-Risk Cytogenetics in Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

The Rules of T-cell Engagement: Current State of CAR T-cells and Bispecific Antibodies in B-cell Lymphomas

[T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?]

Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma